J&J latest pharma firm to volunteer pricing data

pharmafile | February 28, 2017 | News story | Manufacturing and Production, Medical Communications J&J, JJ, Johnson & Johnson 

Johnson & Johnson released its pricing data, as promised, in February and it has simply revealed that its average price increases have been below the 10% mark annually for the last five years. It follows a similar path trodden by MSD, known as Merck in North America, in the release of a brief table of price increases but levelled against the ‘Net Price Change’ that factors in rebates and reimbursements.

The difference with J&J’s presentation is that the webpage that contains the pricing detail, which links directly from its website’s homepage, focuses on ‘Value and Pricing’. In variously easy to slightly more complex infographics, J&J breaks down the pharmaceutical industry hard-line that pricing relates to its value. It also takes time to explain the rebate and reimbursement process that drugs undergo before reaching the market whilst taking the time to explain the supply chain.

Anybody that has not persuaded to stop reading, by this point, is rewarded with a brief table detailing price changes over the last five years, with 2016 List Price Change Average in at 8.5% with a Net Price Change Average of 3.5%.

“Like you, our Janssen colleagues now what it’s like when a loved one faces a medical challenge and we’ve seen the difference that innovative medicines can make for ourselves and for our families. That’s why we know how important it is that the patients who need our medicines get them,” empathises Jennifer Taubert, J&J’s Company Group Chairman, for the Americas, in a video statement.

The price increases read as follows:

  List Price Change Average    Net Price Change Average
  • 7.6%
  • 4.3%
  • 9.0%
  • 4.8%
  • 8.3%
  • 2.5%
  • 9.7%
  • 5.2%
  • 8.5%
  • 3.5%


J&J’s move to release the basic price change average over the last five years comes as the pharmaceutical industry seems to have reached a consensus amongst themselves that List Price changes under 10% are now the gold standard of ‘fair pricing’. It follows moves by Allergan, Novo Nordisk and Takeda in promising that they will keep their prices below 10%.

Ben Hargreaves

Related Content

New warning added to J&J vaccine in US

The FDA has made the decision to add a warning to the fact sheet for …

J&J’s Tremfya sees positive results for post-TNFi psoriatic arthritis

Johnson & Johnson’s interleukin-23 (IL-23) Tremfya (guselkumab) has shown positive results in Phase IIIb trials, …

J&J COVID-19 vaccine to resume Europe rollout

The Johnson & Johnson COVID-19 vaccine will continue its rollout in Europe, following a review …

Latest content